Michael Morrissey, Exelixis CEO

Ex­elix­is drug fails PhI­II lung can­cer tri­al with Cabome­tyx and Tecen­triq com­bo

Ex­elix­is’ tri­al of Cabome­tyx and Tecen­triq for pa­tients with metasta­t­ic non-small cell lung can­cer failed to meet its goal of ex­tend­ing over­all sur­vival com­pared to chemother­a­py.

The com­pa­ny shared the fail­ure in a brief press re­lease Thurs­day af­ter­noon. It said it will share oth­er, sec­ondary out­comes at the tri­al at a fu­ture med­ical meet­ing.

The 366 pa­tients in the tri­al re­ceived Ex­elix­is’ drug Cabome­tyx in com­bi­na­tion with Roche’s Tecen­triq or do­c­etax­el. All of the pa­tients had been treat­ed pre­vi­ous­ly with an­ti-PD-1 or PD-L1 drugs that failed to stop their can­cers.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.